Início › Câncer de Pulmão de Não Pequenas Células › Maryland

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Maryland

76 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Maryland.

Cidades em Maryland

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Luminis Health Anne Arundel Medical Center, Annapolis
Greater Baltimore Medical Center, Baltimore
Sinai Hospital of Baltimore, Baltimore
e mais 7

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Maryland Oncology Hematology (MOH) ( Site 8102), Rockville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06623422

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

National Institutes of Health Clinical Center, Bethesda

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT02146170

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Ascension Saint Agnes Hospital, Baltimore

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06472245

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Local Institution - 0123, Baltimore

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07680764

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #14, Baltimore

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

MedStar Franklin Square Medical Center ( Site 0033), Baltimore

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06780085

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Johns Hopkins University, Baltimore

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

UM Upper Chesapeake Hematology and Oncology - Aberdeen, Aberdeen
UPMC Western Maryland, Cumberland

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Baltimore

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06996782

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Johns Hopkins University of Medicine, Baltimore

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784

DK222 Study at Hopkins

Johns Hopkins Hospital, Baltimore

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07140315

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Maryland Oncology Hematology, P.A., Annapolis
Maryland Oncology Hematology, P.A., Bethesda
Maryland Oncology Hematology, PA, Brandywine
e mais 5

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07144280

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

National Institutes of Health Clinical Center, Bethesda

RecrutandoEstudo observacional

Idades de 18 a 120 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT02682667

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Sidney Kimmel Cancer Center - Bayview Campus, Baltimore

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05498428

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center, Bethesda

RecrutandoFase 2

Idades de 18 a 72 · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT03412877

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Maryland Oncology Hematology, P.A., Annapolis
Maryland Oncology Hematology, P.A., Bethesda
Maryland Oncology Hematology, P.A., Brandywine
e mais 5

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07222566

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Maryland, Baltimore
Maryland Oncology Hematology P A, Silver Spring

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07154290

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Bethesda
Research Site, Frederick
Research Site, Silver Spring
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

University of Maryland, Baltimore
Johns Hopkins Bayview Medical Center, Baltimore
James M Stockman Cancer Institute, Frederick

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0505, Annapolis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Annapolis

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06357533

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Baltimore

RecrutandoFase 2

Idades de 18 a 95 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Frederick Health Hospital- James M Stockman Cancer Institute, Frederick

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06712316

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0702, Annapolis
Maryland Oncology Hematology - Columbia, Columbia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06875310

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center, Bethesda

RecrutandoFase 1

Idades de 18 a 120 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06066138

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

University of Maryland Greenebaum Cancer Center, Baltimore
Sinai Hospital of Baltimore, Baltimore
Medstar Franklin Square, Baltimore
e mais 2

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT06745882

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Bethesda
Research Site, Bethesda

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Baltimore

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06767514

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Johns Hopkins, Baltimore

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07349537

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

United Theranostics, Glen Burnie

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Sidney Kimmel Comprehensive Cancer Center, Baltimore

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04613596

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

John Hopkins Medical Center, Baltimore

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 11 de set. de 2026 · NCT04410796

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
Walter Reed National Military Medical Center, Bethesda

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Johns Hopkins Bayview Medical Center, Baltimore
USO - Maryland Oncology Hematology, Columbia

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Baltimore
Research Site, Brandywine

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07291037

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06343402

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center, Bethesda

RecrutandoFase 2

Idades de 18 a 72 · Todos os sexos · Atualizado em 31 de ago. de 2026 · NCT02133196

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site, Bethesda

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT06350097

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.